Antineoplastic - mTOR Kinase Inhibitors

Antineoplastic mTOR kinase inhibitors are targeted therapeutic agents that suppress the catalytic activity of the mammalian target of rapamycin (mTOR), a key serine/threonine protein kinase in the PI3K/Akt/mTOR signaling axis By competitively binding the ATP-catalytic domain of the kinase to inhibit both mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2)—or via broader class designations that encompass allosteric rapalogs—these agents block downstream cellular proliferation, protein translation...

Antineoplastic mTOR kinase inhibitors are targeted therapeutic agents that suppress the catalytic activity of the mammalian target of rapamycin (mTOR), a key serine/threonine protein kinase in the PI3K/Akt/mTOR signaling axis By competitively binding the ATP-catalytic domain of the kinase to inhibit both mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2)—or via broader class designations that encompass allosteric rapalogs—these agents block downstream cellular proliferation, protein translation...

By competitively binding the ATP-catalytic domain of the kinase to inhibit both mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2)—or via broader class designations that encompass allosteric rapalogs—these agents block downstream cellular proliferation, protein translation, and angiogenesis, thereby promoting tumor cell apoptosis

Clinically and investigatively, drugs within this therapeutic group are primarily utilized in oncology to treat advanced malignancies, most notably renal cell carcinoma, hormone receptor–positive advanced breast cancer, neuroendocrine tumors, and selected soft tissue sarcomas

Clinically and investigatively, drugs within this therapeutic group are primarily utilized in oncology to treat advanced malignancies, most notably renal cell carcinoma, hormone receptor–positive advanced breast cancer, neuroendocrine tumors, and selected soft tissue sarcomas